Radiation Toxicity in MDA5+ and PL7-positive Dermatomyositis: Heightened Risk in Autoimmune Subtypes

Abstract

PurposeTo increase awareness of peri-radiotherapy (RT) intervention that may unduly heighten the risk of toxicity in lung cancer patients and encourage molecular testing and pre-treatment consultation with rheumatology for patients with active autoimmune conditions. Materials and MethodsA 42-year-old male with autoimmune disease was diagnosed with a non-small cell lung cancer. He received 4 cycles of pemetrexed/cisplatin with proton therapy (PT) delivered halfway through for a bronchial stump positive margin. After completing the first half of adjuvant chemotherapy, he was given 61.6Gy in 28 fractionations of PT. Before re-starting chemotherapy, he experienced a dry cough and later shortness of breath (SOB) which resolved with an aggressive steroid taper. After completing his 4th cycle of cisplatin/pemetrexed, his SOB and cough worsened. He was admitted for an urgent bronchoscopy with debridement of the distal trachea and proximal left main bronchus. He received high dose steroids again and another bronchoscopy, revealing a tracheoesophageal (TE) fistula. Rheumatology identified a MDA5+ and PL7-positive dermatomyositis subtype at this time, known to be associated with rare ulcerative symptoms. ResultsA rare MDA5+ and PL7-positive dermatomyositis subtype, discovered post-treatment, most likely contributed to SOB and cough following chemotherapy and PT resulting in bronchoscopy of the irradiated field. A combination of these factors may have contributed to the TE fistula. ConclusionPatients with autoimmune disease should be carefully evaluated for rare underlying subtypes that could pose danger to treatment. Oncologists should continue to be vigilant about underlying genetic predisposing factors that lead to exacerbated toxicity. Immunosuppressive agents given with RT may be considered for patients with autoimmune disease. Avoidance of biopsy, tissue manipulation, debridement, or any form of soft or hard tissue violation needs to be discussed across the multidisciplinary spectrum to avoid non-healing lesions shortly after RT.